Ortler Global Tibbi Gerecler Anonim Sirketi appears in FDA 510(k) records as the applicant for the FRAXION Spinal Fixation System, cleared under K262091 with a decision date of September 17, 2026. The filing is a Traditional premarket notification reviewed by the Orthopedic panel, and the decision description recorded is Substantially Equivalent. The company name is the legal applicant on the filing; no parent, brand or ownership relationship is documented in the available records. [1][4][5]

The K262091 clearance and its scope

K262091 was received on June 22, 2026 and decided on September 17, 2026, a Traditional submission with no third-party review flag. The device is listed as a Thoracolumbosacral Pedicle Screw System in Class 2 under regulation 888.3070, product code NKB, with the advisory committee recorded as Orthopedic. The decision code is SESE, described as Substantially Equivalent, and the filing indicates a Summary rather than a statement. [1][4]

An independent device database reports the same clearance date and describes the device as active as of October 22, 2026, noting that 510(k) clearance is not time-limited and that no FDA recalls were found in its synced data. A separate tool lists K262091 as substantially equivalent on September 17, 2026 after 87 days, with no recalls tied to it in FDA's recall database. These are third-party database observations, not FDA statements of safety or performance. [6][7]

Documented device description

Published device documentation describes the FRAXION Spinal Fixation System as a top-loading, multiple-component posterior spinal fixation system intended to provide immobilization and stabilization of non-cervical spinal segments in skeletally mature patients as an adjunct to fusion using autograft or allograft. The same record classifies the device as Therapeutic and lists the primary predicate as the ArtFX Spinal Fixation System under product code NKB. [4][5]

What the filing record does and does not establish

The linked collection contains one 510(k) record, and that single record carries a Substantially Equivalent decision. This is a snapshot of the filings assembled for this profile, not a measure of the company's total portfolio, sales or safety history. No premarket approval, De Novo grant or recall entry appears among the linked records. [1][6]

The FDA record lists an Ankara, Turkey address for the applicant. That is a filing address, and the available records do not establish a headquarters, ownership structure, website, customer base or commercial availability for the company or the device. [1][7]

Reading the record for industry purposes

For regulatory and competitive tracking, K262091 places Ortler Global Tibbi Gerecler Anonim Sirketi in the NKB pedicle screw category with a September 2026 clearance and a named predicate. The Innolitics record states that the information presented demonstrates substantial equivalence of the subject device, and the FDA decision description matches that outcome. Any inference beyond the documented clearance, such as market entry or clinical use, is not supported by these records. [1][4][5]